Premium
O2‐11‐02: Comparison of All‐Cause Mortality Rate and Economic Burden Between Newly Diagnosed Alzheimer's Disease Patients Who Received Anti‐Dementia Treatment Versus Not: A Longitudinal Retrospective Study
Author(s) -
Black Christopher M.,
Hu Xiaohan,
Khandker Rezaul Karim,
Ambegaonkar Baishali M.,
Kariburyo Furaha,
Xie Lin,
Baser Onur,
Yuce Huseyin
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.455
Subject(s) - medicine , rivastigmine , galantamine , dementia , donepezil , hazard ratio , retrospective cohort study , proportional hazards model , population , national death index , diagnosis code , propensity score matching , disease , pediatrics , confidence interval , environmental health
O2-11-02 COMPARISON OFALL-CAUSEMORTALITY RATE AND ECONOMIC BURDEN BETWEEN NEWLY DIAGNOSED ALZHEIMER’S DISEASE PATIENTS WHO RECEIVED ANTI-DEMENTIATREATMENT VERSUS NOT: A LONGITUDINAL RETROSPECTIVE STUDY Christopher M. Black, Xiaohan Hu, Rezaul Karim Khandker, Baishali M. Ambegaonkar, Furaha Kariburyo, Lin Xie, Onur Baser, Huseyin Yuce, Merck&Co., Inc., Kenilworth, NJ, USA; Temple University, Philadelphia, PA, USA; 3 STATinMED Research, Ann Arbor, MI, USA; Center for Innovation&Outcomes Research, Department of Surgery, New York, NY, USA; New York City College of Technology, Brooklyn, NY, USA. Contact e-mail: xiaohan.hu@merck.com